| Drug Name |
Nimodipine |
| Drug ID |
BADD_D01569 |
| Description |
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm. |
| Indications and Usage |
For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits. |
| Marketing Status |
approved; investigational |
| ATC Code |
C08CA06 |
| DrugBank ID |
DB00393
|
| KEGG ID |
D00438
|
| MeSH ID |
D009553
|
| PubChem ID |
4497
|
| TTD Drug ID |
D0XN1F
|
| NDC Product Code |
70966-0012; 49452-4854; 63739-797; 43898-0117; 62973-300; 68084-912; 10888-8124; 65655-0012; 58624-0495; 23155-512; 67877-297; 69452-209; 10888-8113; 58159-047; 76055-0047; 24338-230; 24338-260 |
| UNII |
57WA9QZ5WH
|
| Synonyms |
Nimodipine | Bay e 9736 | e 9736, Bay | Brainal | Calnit | Kenesil | Nymalize | Nimodipin Hexal | Hexal, Nimodipin | Nimodipin-ISIS | Nimodipin ISIS | Nimodipino Bayvit | Bayvit, Nimodipino | Nimotop | Remontal | Admon | Modus |
